Market closed
Exagen/$XGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exagen
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Ticker
$XGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
212
Website
Exagen Metrics
BasicAdvanced
$72M
-
-$0.83
1.40
-
Price and volume
Market cap
$72M
Beta
1.4
52-week high
$4.64
52-week low
$2.67
Financial strength
Current ratio
2.699
Quick ratio
2.212
Long term debt to equity
226.866
Total debt to equity
244.895
Interest coverage (TTM)
-6.10%
Management effectiveness
Return on assets (TTM)
-16.77%
Return on equity (TTM)
-93.78%
Valuation
Price to revenue (TTM)
1.318
Price to book
7.45
Price to tangible book (TTM)
7.45
Price to free cash flow (TTM)
-5.318
Growth
Revenue change (TTM)
5.89%
Earnings per share change (TTM)
-38.03%
3-year revenue growth (CAGR)
4.83%
3-year earnings per share growth (CAGR)
-20.95%
Exagen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Exagen stock?
Exagen (XGN) has a market cap of $72M as of April 06, 2025.
What is the P/E ratio for Exagen stock?
The price to earnings (P/E) ratio for Exagen (XGN) stock is 0 as of April 06, 2025.
Does Exagen stock pay dividends?
No, Exagen (XGN) stock does not pay dividends to its shareholders as of April 06, 2025.
When is the next Exagen dividend payment date?
Exagen (XGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Exagen?
Exagen (XGN) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.